Preview

Epilepsy and paroxysmal conditions

Advanced search

THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) AS TREATMENT OF DEPRESSION IN PATIENTS WITH EPILEPSY

https://doi.org/10.17749/2077-8333.2016.8.3.011-018

Full Text:

Abstract

The current possibilities of treatment of depression in epilepsy were represented. Depression is one of the most frequent psychiatric comorbidities  in epilepsy. The prevalence of depression  ranges from 10 to 80%, and most  often found in patients with focal epilepsy resistant to antiepileptic therapy. Depression in patients with epilepsy are not often diagnosed and therefore not treated. A number of common epilepsy and depression  pathogenetic mechanisms, such as impaired metabolism  of certain neurotransmitters  in the central nervous system, especially serotonin was descripted. Based on this, the most  promising  drugs in the treatment  of depression  in epilepsy  are now the selective  serotonin  reuptake inhibitor (SSRI), such  as escitalopram.  Objective. The primary objectives  were to evaluate the efficacy and safety  of escitalopram in treating depressive symptoms. Materials and  methods. The study involved 68 patients aged 19-69 years with cryptogenic and focal epilepsy and different disease duration (from 5 to 21 years), different types of seizures and suffering depression  interictal (between  2 and 5.5 years). Depression Rating Scale of Montgomery-Asberg (MADRS) was used.  To assess the severity of the patient ’s condition at the time of the survey, a global assessment of disease severity (CGI-S) and the global assessment of the mental state (CGI-I) were used. While taking escitalopram (10-20 mg per day.), all patients received basic anticonvulsant therapy. Results.  During follow-up the patients with epilepsy who took  escitalopram,  proconvulsant  effect  were not  denoted.  In assessing depressive  symptoms improved  markedly. Against the background of escitalopram no deterioration was marked, no sedation, addiction to the drug was observed, minimum drug interactions with anticonvulsants was registered. Conclusion. The results described observation program suggests a safe and effective treatment of escitalopram epilepsy patients with depression,  it is well tolerated, low drugdrug interactions, as well as improve the quality of life of patients.

For citations:


Solomatin Yu.V., Rubleva Yu.V. THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) AS TREATMENT OF DEPRESSION IN PATIENTS WITH EPILEPSY. Epilepsy and paroxysmal conditions. 2016;8(3):11-18. (In Russ.) https://doi.org/10.17749/2077-8333.2016.8.3.011-018

Views: 1646


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)